Choose a country to view content specific to your location
Choose a country to view content specific to your location
Point-of-care diagnostics are reshaping how and where patients access healthcare. However, challenges around enzyme stabilization, cost, and logistics can limit their reach.
Speaker: William Ferreira, R&D Team Leader at Meridian Life Science
Learn more about our solutions for:
Discover how Meridian’s technologies support the development of assays suitable for clinical labs, pharmacies, and at-home use.
The COVID-19 pandemic has left a lasting impact on diagnostic immunoassays, with emerging evidence linking SARS-CoV-2 infection to increased antibody-mediated immunoassay interference. This presentation explores the rise in interference, particularly from rheumatoid factor (Rf), and its implications for assay accuracy.
View this webinar to learn about:
The session also highlights the role of passive, active, and universal blockers in neutralizing interfering antibodies — and showcases Meridian Life Science’s solutions for ELISA, CLIA, and LFA platforms.
Speaker: John Francois, Product Manager
As the IVD industry continues to evolve, new regulations frequently come into place to better control an innovative and growing industry. Molecular IVDs in particular are experiencing tighter regulations regarding the presence of appropriate controls within the assay. All tests must include both positive and negative controls which are subjected to the whole testing process, including the extraction step. Novel co-extracted exogenous controls are providing cutting edge solutions for monitoring RNA or DNA analysis including the detection of potential inhibition. These controls can be used across a variety of sample types and assays, representing a significant advantage over traditional spike-in controls.
Speakers:
Michele Amasio, Ph.D. (Research and Development Senior Manager, Meridian Bioscience)
Moderator:
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
As precision medicine in oncology advances, selecting the right genomic analysis method is key to obtaining accurate and actionable insights. Whether detecting MRD, identifying mutations, or developing liquid biopsy assays, the choice between qPCR, targeted NGS, and whole-genome sequencing directly impacts clinical utility.
Speaker: Dale Clash, Strategic Marketing Manager (Molecular)
VIEW THIS WEBINAR TO LEARN ABOUT:
Join us to gain a deeper understanding of these powerful technologies and how Meridian can support your assay development with innovative solutions tailored to your needs.
Despite gaining traction in diagnostics, molecular Point-of-Care (POC) tests face challenges related to accessibility, stability, and ease of workflow.
Due to infrastructure limitations, especially in remote areas, there is often a lack of necessary resources for appropriately storing reagents, and complex workflows are frequently difficult to implement in non-laboratory settings.
VIEW THIS WEBINAR TO LEARN ABOUT:
Don’t miss this opportunity to gain valuable insights from experts in molecular reagent development.
With over 12 different types of human papilloma virus (HPV) that can cause cancer, it is the leading cause of cervical cancer in women. The HPV/Pap smear co-test has improved the accuracy of cervical cancer screening; however the test has several limitations. Recent advancements in molecular diagnostics have led to the development of genotype-specific HPV tests that accurately detect and differentiate HPV strains, including high-risk oncogenic types such as HPV-16 and HPV-18.
In this webinar you will:
Speaker: Steve Hawkins, Ph.D., Meridian Life Science Molecular Product Manager
This webinar explores the groundbreaking impact of innovative next-generation sequencing (NGS) enzymes, library preparation kits and services on reshaping the sequencing landscape and accelerating the democratization of NGS in diagnostics. Learn about the newest eco-conscious and cost-effective solutions in NGS reagents, that eliminate cold-chain requirements and decrease NGS workflow-associated carbon footprint.
IN THIS WEBINAR, YOU WILL LEARN ABOUT:
Speakers:
Michele Amasio, Ph.D., Senior Manager, R&D – Molecular
Lina Gasiūnaitė, Ph.D., Team Leader, R&D – Molecular
With the global increase of sexually transmitted infections (STIs), the need for accessible and accurate STI diagnostic solutions has never been more critical. Traditional testing methods are hindered by several barriers, including limited accessibility and STI-related stigma. This is further compounded by the challenge of asymptomatic infections, which deter initial testing. However, the unprecedented adoption of at-home testing and telemedicine that developed during the COVID-19 pandemic has facilitated the expansion of at-home and self-collection assays for several diseases, such as STIs. Join us as we delve into the changing landscape of STI testing, highlighting the new developments in at-home testing and the molecular and immunoassay reagent solutions for developing new STI assays.
IN THIS WEBINAR, YOU WILL LEARN ABOUT:
Speakers:
Steve Hawkins, Ph.D., Merdian Life Science Molecular Product Manager
Ryan Hughes, Ph.D, Merdian Life Science Immuno Product Manager
As regulations tighten, find out how to improve process control through every step of a molecular assay, from samples to results!
DNA genotyping is a powerful technology that allows the identification of genetic variations that can lead to an increased risk of developing certain diseases. Additionally, genotyping has a fundamental role in companion diagnostics, as it enables the characterization of patients’ genetic profiles that can be used to guide treatment decisions.
Here, we will introduce two novel master mixes developed to provide PCR-based identification of mutations directly from the clinical samples, such as blood, plasma or FFPE tissue, bypassing DNA extraction and streamlining the analysis of both liquid and tissue biopsies.
Speakers:
Steve Hawkins, Ph.D., Product Marketing Manager
Join our in-house experts William Ferreira, Ph.D. and Steve Hawkins, Ph.D., for their latest webinar where they share their insights on the newest range of Lyo-Ready Genotyping Direct qPCR Master mixes that support commercial assays designed to detect mutations.
In this presentation, you will learn how to detect single nucleotide polymorphisms (SNPs) directly from blood, plasma, urine, stool or FFPE tissue (down to 1 copy/reaction) using a simplified workflow that eliminates the need for nucleic acid extraction.
Speakers:
William Ferreira, Ph.D., R&D Team Leader
Steve Hawkins, Ph.D., Product Marketing Manager
Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 diseases and an extensive range of specialty qPCR/RT-qPCR master mixes and molecular enzymes all manufactured under ISO13485 regulations.
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.
